Oct 2026· American Journal of Hypertension· Vol 39 Supplement_1, pp.
S11-S17
· 0 citations
Medicine
TL;DR
Recognizing aldosterone dysregulation as a systemic cardio-renal-metabolic disorder has important implications for risk stratification and targeted therapies with a focus on cardiovascular outcomes.
This review distinguishes aldosterone excess from MR activation and proposes a nephrology-focused clinical framework separating established MRA indications, evaluation for primary aldosteronism, and the unestablished cardiorenal outcome role of aldosterone synthase inhibitors (ASIs).
Mehmet Kanbay, Rama Al-Shiab, Ermeena Shah et al.· Nephrology, Dialysis and Tra...· 0 citations
ABSTRACT Hypertension is a major global health burden and a leading contributor to cardiovascular disease and chronic kidney disease (CKD). Despite the availability of multiple antihypertensive therapies, blood pressure control remains suboptimal, and a significant proportion of patients develop resistant hypertension,...
Gavin B. Chapman, Dan Pugh, N. Dhaun· Clinical Kidney Journal· 0 citations
The epidemiology and mechanisms linking cortisol excess to CKM dysfunction are summarized, and the need for clinical trials, standardized diagnostic thresholds, and assays to enable integration of cortisol-targeted therapies into management pathways to mitigate residual CKM risk is highlighted.
Muhammad Shahzeb Khan, Muhammad Sameer Arshad, Deepak L. Bhatt et al.· European Heart Journal· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.